Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novelix PharmaceuticalsBOM:536565 +3.89%48 PB Ratio is 3.47 as of Aug. 19, 2026, which is 351% above its 10-year median of 0.77. GuruFocus rates BOM:536565 with a GF Score™ of 48/100. The stock has 8 warning signs investors should review. Among 112 Medical Distribution companies, Novelix Pharmaceuticals ranks worse than 83.04% on this metric.
Novelix Pharmaceuticals Ltd stock PB Ratio (=3.49) is close to 10-year high of 3.75.
The historical rank and industry rank for Novelix Pharmaceuticals's PB Ratio or its related term are showing as below:
BOM:536565'
s PB Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.77 Max: 3.75
Current: 3.46
During the past 13 years, Novelix Pharmaceuticals's highest PB Ratio was 3.75. The lowest was 0.14. And the median was 0.77.
BOM:536565's PB Ratio is ranked worse than 83.04% of 112
companies
in the Medical Distribution industry
Industry Median: 1.03
vs BOM:536565: 3.46
During the past 12 months, Novelix Pharmaceuticals's average Book Value Per Share Growth Rate was 25.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 35.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 0.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Novelix Pharmaceuticals was 129.30% per year. The lowest was -15.00% per year. And the median was 1.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Novelix Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Novelix Pharmaceuticals (BOM:536565) has a PB Ratio of 3.47 as of Aug. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Novelix Pharmaceuticals and its competitors. This is 351% above median its historical median of 0.77. Over the past decade, Novelix Pharmaceuticals' PB Ratio has ranged from 0.14 to 3.75. According to the industry distribution chart, Novelix Pharmaceuticals ranks #93 out of 112 companies in the Medical Distribution industry, placing it in the top 83%.
Is Novelix Pharmaceuticals' PB Ratio too high?
Novelix Pharmaceuticals' current PB Ratio of 3.47 is 351% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 3.75. The Medical Distribution industry median PB Ratio is 1.03. Novelix Pharmaceuticals' value of 3.47 is 236.9% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #93 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Novelix Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #93 out of 112 companies for PB Ratio. This places Novelix Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.03. Novelix Pharmaceuticals' value of 3.47 is 236.9% above this benchmark. Historically, Novelix Pharmaceuticals' own PB Ratio has ranged from 0.14 to 3.75 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 1.03, Novelix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current PB Ratio of 3.47 is 236.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current PB Ratio is 3.47, which is 351% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Novelix Pharmaceuticals (BOM:536565) has a current PB Ratio of 3.47. The current PB Ratio is 3.47, which is 351% above median its 10-year median of 0.77 and 236.9% above the Medical Distribution industry median of 1.03. Novelix Pharmaceuticals' overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current PB Ratio is 3.47 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
48GF Score
Get the complete analysis for BOM:536565
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
